Drug Profile
KD 382
Alternative Names: KD-382; Tetravalent dengue vaccineLatest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Kaketsuken
- Developer KM Biologics; Mahidol University
- Class Attenuated vaccines; Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Dengue